• Publications
  • Influence
MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.
MDM2 expression, combined with increased p53 expression, is associated with reduced survival in several cancers, but is particularly of interest in renal cell carcinoma (RCC) where evidence suggestsExpand
  • 21
  • 1
  • PDF
5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors.
Maternal embryonic leucine zipper kinase (MELK) is involved in several key cellular processes and displays increased levels of expression in numerous cancer classes (colon, breast, brain, ovary,Expand
  • 3
Abstract B242: Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase for standalone and combination therapy with AuroraB inhibitors in colorectal cancer.
The mitotic machinery is a validated target for potential drug therapies in cancer. Anti-mitotic drugs like vinca alkaloids and taxanes interfering with microtubules are important classes ofExpand
Abstract A243: Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors.
The family of Pim kinases emerged as a novel and interesting target with significant potential for therapeutic intervention in cancer. All three members of the family Pim-1, Pim-2 and Pim-3 wereExpand
Abstract 2160: Development of selective MELK kinase inhibitors for cancer treatments.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Maternal embryonic leucine zipper kinase (MELK) is an atypical member of the AMPK family of serine-threonine kinases thatExpand
Abstract 3245: Identification of potent, dual PIM/FLT3 kinase inhibitors for AML treatment.
Acute myeloid leukemia (AML) is a highly heterogeneous disease with numerous signaling pathways that contribute to its pathogenesis. Advances in our understanding of molecular mechanisms of AMLExpand